Microcaps
Join the SmallCapReview mailing list

   
   
   
   
   

 

   

 


Transition Therapeutics (Nasdaq: TTHI)

A biopharmaceutical company that engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimers disease and neuropsychiatric disorders; TT-301 and TT-302, which are in Phase I clinical trial for the treatment of rheumatoid arthritis, Alzheimers disease, intracerebral hemorrhage, and traumatic brain injury; and TT401/402, a Phase I clinical trial product to treat diabetes. 

The company also has a pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and Eli Lilly and Company.

More on TTHI


Omeros Corp. (Nasdaq: OMER)

A clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. 

The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. 

Omeros has five clinical development programs.

More on OMER